Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Inappropriate schedule of product administration, Magnetic resonance imaging
Clinical narrative: lost most of my body strength; 1st boster dose: 04Oct2022, 2nd booster dose: 21Oct2022; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 79-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 21Oct2022 as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "BPH", start date: 01Jan2021 (ongoing), notes: Urinary incontinence; No surgery; "Lower Cholesterol" (ongoing); "Avoid acid reflux" (ongoing); "To get to sleep/sleep aid" (ongoing); "Urinary incontinence" (unspecified if ongoing); "Reduce wheezing" (ongoing). Concomitant medication(s) included: ATORVASTATIN oral taken for blood cholesterol abnormal, start date: 01Jan2021 (ongoing); FAMOTIDINE oral taken for gastrooesophageal reflux disease, start date: 27May2022 (ongoing); QUETIAPINE FUMARATE oral taken for sleep disorder, start date: 01Jan2021 (ongoing); PANTOPRAZOLE oral taken for gastrooesophageal reflux disease, start date: 01Jan2021 (ongoing); WIXELA INHUB nasal taken for wheezing, start date: 15Jun2021 (ongoing). Vaccination history included: BNT162b2 (DOSE 3 (BOOSTER), SINGLE; lot number: EN9474, route of administration: intramuscular, anatomical location: upper left arm,administration time: 14:00), administration date: 04Oct2022, for COVID-19 Immunization, reaction(s): "high blood pressure", "loss of strength"; Bnt162b2 (DOSE 1, SINGLE; Anatomical location: Upper left arm, Route of administration: Intramuscular), for COVID-19 Immunization; Bnt162b2 (DOSE 2, SINGLE; Anatomical location: Upper left arm, Route of administration: Intramuscular), for COVID-19 Immunization. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 21Oct2022, outcome "unknown", described as "1st boster dose: 04Oct2022, 2nd booster dose: 21Oct2022"; ASTHENIA (non-serious) with onset 22Oct2022, outcome "unknown", described as "lost most of my body strength". Relevant laboratory tests and procedures are available in the appropriate section.   Additional information: There were no prior vaccination. Lost most of my body strength the morning following my bivalent inoculation. No obvious error.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.  Follow-up (30Nov2022): This is a spontaneous follow-up report from a contactable consumer. This consumer (patient) reported in response to Non-HCP letter sent via follow-up letter which included that: Updated information included: Relevant medical history updated, concomitant medications added, additional information updated with prior vaccination details.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.  Follow up (01Feb2023): This is a spontaneous follow up report from a contactable consumer. This consumer reporter in response to Non-HCP letter sent that included: Updated information included: Classification removed. Reporter slider#01 Fax number updated. Reporter slider #02 added. Height and weight added. Lab test added. Best doctor information added. Added event asthenia. Added clinical information.   The information on the batch/lot number for [BNT162B2, BNT162B2 OMI BA.4-5] has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : PFIZER INC-PV202200086338 same patient/drug, different dose number/event;